1. From a genomic risk model to clinical trial implementation in a learning health system: the ProGRESS Study
- Author
-
Vassy, Jason L, Dornisch, Anna M, Karunamuni, Roshan, Gatzen, Michael, Kachulis, Christopher J, Lennon, Niall J, Brunette, Charles A, Danowski, Morgan E, Hauger, Richard L, Garraway, Isla P, Kibel, Adam S, Lee, Kyung Min, Lynch, Julie A, Maxwell, Kara N, Rose, Brent S, Teerlink, Craig C, Xu, George J, Hofherr, Sean E, Lafferty, Katherine A, Larkin, Katie, Malolepsza, Edyta, Patterson, Candace J, Toledo, Diana M, Donovan, Jenny L, Hamdy, Freddie, Martin, Richard M, Neal, David E, Turner, Emma L, Andreassen, Ole A, Dale, Anders M, Mills, Ian G, Batra, Jyotsna, Clements, Judith, Cussenot, Olivier, Cybulski, Cezary, Eeles, Rosalind A, Fowke, Jay H, Grindedal, Eli Marie, Hamilton, Robert J, Lim, Jasmine, Lu, Yong-Jie, MacInnis, Robert J, Maier, Christiane, Mucci, Lorelei A, Multigner, Luc, Neuhausen, Susan L, Nielsen, Sune F, Parent, Marie-Élise, Park, Jong Y, Petrovics, Gyorgy, Plym, Anna, Razack, Azad, Rosenstein, Barry S, Schleutker, Johanna, Sørensen, Karina Dalsgaard, Travis, Ruth C, Vega, Ana, West, Catharine ML, Wiklund, Fredrik, Zheng, Wei, Committee, Profile Steering, Committee and Collaborators, IMPACT Study Steering, Consortium, PRACTICAL, Program, Million Veteran, and Seibert, Tyler M
- Subjects
Biological Sciences ,Biomedical and Clinical Sciences ,Genetics ,Health Services and Systems ,Health Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Human Genome ,Urologic Diseases ,Prevention ,Prostate Cancer ,Health Services ,Cancer ,4.2 Evaluation of markers and technologies ,Good Health and Well Being - Abstract
ABSTRACT: Background: As healthcare moves from a one-size-fits-all approach towards precision care, individual risk prediction is an important step in disease prevention and early detection. Biobank-linked healthcare systems can generate knowledge about genomic risk and test the impact of implementing that knowledge in care. Risk-stratified prostate cancer screening is one clinical application that might benefit from such an approach. Methods: We developed a clinical translation pipeline for genomics-informed prostate cancer screening in a national healthcare system. We used data from 585,418 male participants of the Veterans Affairs (VA) Million Veteran Program (MVP), among whom 101,920 self-identify as Black/African-American, to develop and validate the Prostate CAncer integrated Risk Evaluation (P-CARE) model, a prostate cancer risk prediction model based on a polygenic score, family history, and genetic principal components. The model was externally validated in data from 18,457 PRACTICAL Consortium participants. A novel blended genome-exome (BGE) platform was used to develop a clinical laboratory assay for both the P-CARE model and rare variants in prostate cancer-associated genes, including additional validation in 74,331 samples from the All of Us Research Program. Results: In overall and ancestry-stratified analyses, the polygenic score of 601 variants was associated with any, metastatic, and fatal prostate cancer in MVP and PRACTICAL. Values of the P-CARE model at ≥80th percentile in the multiancestry cohort overall were associated with hazard ratios (HR) of 2.75 (95% CI 2.66-2.84), 2.78 (95% CI 2.54-2.99), and 2.59 (95% CI 2.22-2.97) for any, metastatic, and fatal prostate cancer in MVP, respectively, compared to the median. When high– and low-risk groups were defined as P-CARE HR>1.5 and HR
- Published
- 2024